Identification of differentially expressed serum proteins in gastric adenocarcinoma.

UNLABELLED Gastric adenocarcinoma is an aggressive cancer with poor prognosis. Blood based biomarkers of gastric cancer have the potential to improve diagnosis and monitoring of these tumors. Proteins that show altered levels in the circulation of gastric cancer patients could prove useful as putative biomarkers. We used an iTRAQ-based quantitative proteomic approach to identify proteins that show altered levels in the sera of patients with gastric cancer. Our study resulted in identification of 643 proteins, of which 48 proteins showed increased levels and 11 proteins showed decreased levels in serum from gastric cancer patients compared to age and sex matched healthy controls. Proteins that showed increased expression in gastric cancer included inter-alpha-trypsin inhibitor heavy chain H4 (ITIH4), Mannose-binding protein C (MBL2), sex hormone-binding globulin (SHBG), insulin-like growth factor-binding protein 2 (IGFBP2), serum amyloid A protein (SAA1), Orosomucoid 1 (ORM1) and extracellular superoxide dismutase [Cu-Zn] (SOD3). We used multiple reaction monitoring assays and validated elevated levels of ITIH4 and SAA1 proteins in serum from gastric cancer patients. BIOLOGICAL SIGNIFICANCE Gastric cancer is a highly aggressive cancer associated with high mortality. Serum-based biomarkers are of considerable interest in diagnosis and monitoring of various diseases including cancers. Gastric cancer is often diagnosed at advanced stages resulting in poor prognosis and high mortality. Pathological diagnosis using biopsy specimens remains the gold standard for diagnosis of gastric cancer. Serum-based biomarkers are of considerable importance as they are minimally invasive. In this study, we carried out quantitative proteomic profiling of serum from gastric cancer patients to identify proteins that show altered levels in gastric cancer patients. We identified more than 50 proteins that showed altered levels in gastric cancer patient sera. Validation in a large cohort of well classified patient samples would prove useful in identifying novel blood based biomarkers for gastric cancers. This article is part of a Special Issue entitled: Proteomics in India.

[1]  H. Egami,et al.  Comparative effectiveness of the tumour diagnostics, CA 19-9, CA 125 and carcinoembryonic antigen in patients with diseases of the digestive system. , 1987, Gut.

[2]  M. Inoue,et al.  Plasma levels of C-reactive protein and serum amyloid A and gastric cancer in a nested case-control study: Japan Public Health Center-based prospective study. , 2010, Carcinogenesis.

[3]  Hwee Tong Tan,et al.  Mining the gastric cancer secretome: identification of GRN as a potential diagnostic marker for early gastric cancer. , 2012, Journal of proteome research.

[4]  John Greenwood,et al.  LRG1 promotes angiogenesis by modulating endothelial TGFß signalling , 2013, Nature.

[5]  M. Piver,et al.  Serum alpha 1-acid glycoprotein in epithelial ovarian cancer. , 1988, Gynecologic oncology.

[6]  M. Reale,et al.  Synergistic activation of serum amyloid A (SAA) by IL-6 and IL-1 in combination on human Hep 3B hepatoma cell line. Role of PGE2 and IL-1 receptor antagonist. , 1995, Immunological investigations.

[7]  W. Barrett,et al.  Differences among techniques for high‐abundant protein depletion , 2005, Proteomics.

[8]  J. Lee,et al.  Clinicopathologic significance of expression of nuclear factor-κB RelA and its target gene products in gastric cancer patients. , 2012, World journal of gastroenterology.

[9]  N. Anderson,et al.  The Human Plasma Proteome , 2002, Molecular & Cellular Proteomics.

[10]  Xifeng Wu,et al.  Insulin-Like Growth Factor Binding Protein-2 Level Is Increased in Blood of Lung Cancer Patients and Associated with Poor Survival , 2013, PloS one.

[11]  Association between SHBG Asp327Asn (rs6259) polymorphism and breast cancer risk: a meta-analysis of 10,454 cases and 13,111 controls , 2012, Molecular Biology Reports.

[12]  Nandini A. Sahasrabuddhe,et al.  Differential proteomic analysis of synovial fluid from rheumatoid arthritis and osteoarthritis patients , 2014, Clinical Proteomics.

[13]  Kejiang Li,et al.  Is insulin-like growth factor binding protein 2 associated with metastasis in lung cancer? , 2014, Clinical & Experimental Metastasis.

[14]  X. Shu,et al.  Association of endometrial cancer risk with a functional polymorphism (Asp327Asn) in the sex hormone‐binding globulin gene , 2006, Cancer.

[15]  P. K. Smith,et al.  Measurement of protein using bicinchoninic acid. , 1985, Analytical biochemistry.

[16]  A. Axon,et al.  Plasma protein profiles and prognosis in gastric cancer. , 1982, British Journal of Cancer.

[17]  Heng-tong Hu,et al.  Analysis of variabilities of serum proteomic spectra in patients with gastric cancer before and after operation. , 2006, World journal of gastroenterology.

[18]  H. Ramstad,et al.  Clinical significance of elevated serum chromogranin A levels , 2004, Scandinavian journal of gastroenterology.

[19]  H. K. Kim,et al.  Serpin peptidase inhibitor clade A member 1 is a biomarker of poor prognosis in gastric cancer , 2014, British Journal of Cancer.

[20]  O. Nedić,et al.  Molecular forms of the insulin-like growth factor-binding protein-2 in patients with colorectal cancer. , 2014, Experimental and molecular pathology.

[21]  S. Tavazoie,et al.  A microRNA regulon that mediates endothelial recruitment and metastasis by cancer cells , 2011, Nature.

[22]  C. Haglund,et al.  Tumour marker CA 125 in patients with digestive tract malignancies. , 1991, Scandinavian journal of clinical and laboratory investigation.

[23]  Nan Hu,et al.  Global Gene Expression Profiling and Validation in Esophageal Squamous Cell Carcinoma and Its Association with Clinical Phenotypes , 2011, Clinical Cancer Research.

[24]  J. Greenwood,et al.  LRG1 promotes angiogenesis by modulating endothelial TGF-beta signalling (vol 499, pg 306, 2013) , 2013 .

[25]  Chih-Hung Ku,et al.  Evaluation of Serum Amyloid A as a Biomarker for Gastric Cancer , 2006, Annals of Surgical Oncology.

[26]  A. Whitehead,et al.  Serum amyloid A, the major vertebrate acute-phase reactant. , 1999, European journal of biochemistry.

[27]  H. Goudarzi,et al.  Serum Levels of Mannose-Binding Lectin and the Risk of Infection in Pediatric Oncology Patients With Chemotherapy , 2012, Journal of pediatric hematology/oncology.

[28]  Nandini A. Sahasrabuddhe,et al.  Calcium calmodulin dependent kinase kinase 2 - a novel therapeutic target for gastric adenocarcinoma , 2015, Cancer biology & therapy.

[29]  M. de Wit,et al.  The cancer secretome, current status and opportunities in the lung, breast and colorectal cancer context. , 2013, Biochimica et biophysica acta.

[30]  Xiao-qun Zhu,et al.  Expression of insulin-like growth factor binding protein-2 in gastric carcinoma and its relationship with cell proliferation. , 2006, World journal of gastroenterology.

[31]  O. Hashim,et al.  Patients with ovarian carcinoma excrete different altered levels of urine CD59, kininogen-1 and fragments of inter-alpha-trypsin inhibitor heavy chain H4 and albumin , 2010, Proteome Science.

[32]  Bingya Liu,et al.  Proteomic identification of serum biomarkers for gastric cancer using multi-dimensional liquid chromatography and 2D differential gel electrophoresis. , 2012, Clinica chimica acta; international journal of clinical chemistry.

[33]  E. Diamandis,et al.  Strategies for discovering novel cancer biomarkers through utilization of emerging technologies , 2008, Nature Clinical Practice Oncology.

[34]  H. Matsuura,et al.  Prognostic significance of serum al-acid glycoprotein in patients with glioblastoma multiforme: a preliminary communication , 2022 .

[35]  Marie-Christine W. Gast,et al.  The absolute quantification of eight inter‐α‐trypsin inhibitor heavy chain 4 (ITIH4)‐derived peptides in serum from breast cancer patients , 2010, Proteomics. Clinical applications.

[36]  M. Salto‐Tellez,et al.  Cathepsin S mediates gastric cancer cell migration and invasion via a putative network of metastasis-associated proteins. , 2010, Journal of proteome research.

[37]  L. Thiberville,et al.  Inhibition of tumor growth and metastatic spreading by overexpression of inter‐alpha‐trypsin inhibitor family chains , 2002, International journal of cancer.

[38]  K. Ha,et al.  Fucosylated glycoproteomic approach to identify a complement component 9 associated with squamous cell lung cancer (SQLC). , 2011, Journal of proteomics.

[39]  Z. Gucev,et al.  Insulin-like growth factor-binding proteins (IGFBPs) and their regulatory dynamics. , 1996, The international journal of biochemistry & cell biology.

[40]  Krista A. Zanetti,et al.  3'-UTR and functional secretor haplotypes in mannose-binding lectin 2 are associated with increased colon cancer risk in African Americans. , 2012, Cancer research.

[41]  N. Vasudev,et al.  Association of serum amyloid A protein and peptide fragments with prognosis in renal cancer , 2010, British Journal of Cancer.

[42]  M. Piver,et al.  Serum α1-acid glycoprotein in epithelial ovarian cancer , 1988 .

[43]  Michael Hsiao,et al.  Diagnosis of Gastric Malignancy Using Gastric Juice α1-antitrypsin , 2010, Cancer Epidemiology, Biomarkers & Prevention.

[44]  A. Piñeiro,et al.  ITIH4 serum concentration increases during acute-phase processes in human patients and is up-regulated by interleukin-6 in hepatocarcinoma HepG2 cells. , 1999, Biochemical and biophysical research communications.

[45]  Chibo Liu,et al.  Identification of serum amyloid A in the serum of gastric cancer patients by protein expression profiling. , 2012, Oncology letters.

[46]  Wan-Li Liu,et al.  Elevated levels of serum amyloid A indicate poor prognosis in patients with esophageal squamous cell carcinoma , 2012, BMC Cancer.

[47]  M. Loh,et al.  Upregulation of plasma C9 protein in gastric cancer patients , 2010, Proteomics.

[48]  Elise C. Kohn,et al.  The microenvironment of the tumour–host interface , 2001, Nature.

[49]  G. Krejs,et al.  Gastric Cancer: Epidemiology and Risk Factors , 2010, Digestive Diseases.

[50]  Brendan MacLean,et al.  Bioinformatics Applications Note Gene Expression Skyline: an Open Source Document Editor for Creating and Analyzing Targeted Proteomics Experiments , 2022 .

[51]  D. Pectasides,et al.  CEA, CA 19-9, and CA-50 in monitoring gastric carcinoma. , 1997, American journal of clinical oncology.

[52]  M. Loh,et al.  ITIH3 is a potential biomarker for early detection of gastric cancer. , 2010, Journal of proteome research.

[53]  R. Aebersold,et al.  Selected reaction monitoring for quantitative proteomics: a tutorial , 2008, Molecular systems biology.

[54]  D. Korenaga,et al.  Prognostic significance of serum superoxide dismutase activity in patients with gastric cancer , 2002, Gastric Cancer.

[55]  Akhilesh Pandey,et al.  Human Protein Reference Database and Human Proteinpedia as discovery tools for systems biology. , 2009, Methods in molecular biology.

[56]  M. Ychou,et al.  Clinical Significance and Prognostic Value of CA72-4 Compared with CEA and CA19-9 in Patients with Gastric Cancer , 2002, Disease markers.

[57]  S. Kikuchi,et al.  Serum Copper/Zinc Superoxide Dismutase (Cu/Zn SOD) and Gastric Cancer Risk: a Case‐Control Study , 2002, Japanese journal of cancer research : Gann.

[58]  Sandhya Rani,et al.  Human Protein Reference Database—2009 update , 2008, Nucleic Acids Res..

[59]  L. Ellis,et al.  The role of the microenvironment and intercellular cross-talk in tumor angiogenesis. , 2002, Seminars in cancer biology.

[60]  A. Roth.  Curative treatment of gastric cancer: towards a multidisciplinary approach? , 2003, Critical reviews in oncology/hematology.

[61]  W. Rosner,et al.  Stimulation of prostate cancer growth by androgens and estrogens through the intermediacy of sex hormone-binding globulin. , 1996, Endocrinology.

[62]  D. Parkin,et al.  Global cancer statistics in the year 2000. , 2001, The Lancet. Oncology.

[63]  Nandini A. Sahasrabuddhe,et al.  SILAC‐based quantitative proteomic analysis of gastric cancer secretome , 2013, Proteomics. Clinical applications.

[64]  O. Hashim,et al.  Urine of patients with early prostate cancer contains lower levels of light chain fragments of inter‐alpha‐trypsin inhibitor and saposin B but increased expression of an inter‐alpha‐trypsin inhibitor heavy chain 4 fragment , 2013, Electrophoresis.

[65]  A. Jemal,et al.  Global Cancer Statistics , 2011 .

[66]  C. Liao,et al.  Comparative proteomics, network analysis and post-translational modification identification reveal differential profiles of plasma Con A-bound glycoprotein biomarkers in gastric cancer. , 2013, Journal of proteomics.